Mezoo Soars 81% on IPO Day...Kolon TissueGene, Medipost Also Rally[K-Bio Pulse]

[Seungkwon Kim, Edaily Reporter] On the 26th, South Korea's pharmaceutical, biotech, and healthcare sectors saw strong buying interest amid an otherwise cautious market.

Investors focused on companies boasting tangible global clinical results and commercialized digital healthcare technologies. The spotlight shone heavily on the newly listed digital healthcare startup Mezoo, which staged a spectacular debut. Additionally, Kolon TissueGene and Medipost rallied on major global clinical milestones and overseas expansion news, proving the solid fundamentals of K-Bio.

Mezoo Stock Price. (Image=Naver Finance)

Mezoo, Spectacular Kosdaq Debut Driven by 'HiCardi'

Digital healthcare startup Mezoo closed at 39,000 won, an 81% surge from its IPO price on its first trading day. The driving force behind this explosive performance is its flagship wearable ECG solution 'HiCardi.'

This ambulatory remote patient monitoring (aRPM) platform attaches to a patient's chest to track vital signs in real-time, expanding monitoring from ICUs to general wards and home care. It has already been adopted by 53% of domestic tertiary hospitals. Backed by a strong distribution partnership with Dong-A ST, Mezoo plans to use its IPO funds to accelerate its entry into the North American market.

An industry analyst noted, "This surge reflects the market preemptively pricing in HiCardi's unparalleled technology and steep growth potential in North America amid rising global demand for multi-patient monitoring systems."

Kolon Stock Price. (Image=Naver Finance)

Kolon TissueGene, 'Game Changer' Validation Looms for Osteoarthritis Drug

Kolon TissueGene, the developer of the knee osteoarthritis cell and gene therapy 'TG-C', surged 17% to 119,800 won. The rally was triggered by anticipation of the U.S. Phase 3 clinical trial top line data, expected in the second half of this year. Having completed dosing for 1,020 patients across 80 U.S. sites, the trial is now in the final data analysis stage.

The industry is closely watching if the FDA will recognize TG-C as a Disease Modifying Osteoarthritis Drug (DMOAD). Earning this label by improving both pain and cartilage function would make it a global game changer capable of replacing artificial joint surgeries.

An analyst commented "With Phase 3 data collection wrapping up, commercialization is approaching. Expectations for a massive license-out deal with global big pharma are providing strong momentum."

Medipost Stock Price. (Image=Naver Finance)

Medipost, Global 'Cartistem' Expansion and CDMO Synergy

Stem cell therapy developer Medipost closed up 16% at 25,000 won, driven by the global expansion of its severe knee osteoarthritis treatment, 'Cartistem', and a growing CDMO business. Cartistem recently completed Phase 3 trials in Japan and signed a major exclusive distribution agreement with local partner Teikoku Seiyaku.

Medipost also plans to submit a Phase 3 IND application in the U.S. later this year. Additionally, its Cell and Gene Therapy (CGT) CDMO business is accelerating.

Through its Canadian subsidiary OmniaBio, Medipost has secured large-scale North American GMP facilities to absorb growing regional demand. An industry insider noted "Success in Japan has leveled up Medipost's R&D fundamentals. Their two track strategyrolling out a blockbuster drug globally while expanding a highly profitable CDMO infrastructure will serve as a powerful mid-to-long term cash cow."

김승권 (peace@edaily.co.kr)